Emend (fosaprepitant dimeglumine) for injection is approved for use in combination with other antiemetic medicines for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic and highly emetogenic cancer chemotherapy, including high-dose cisplatin. The FDA approval for Emend for injection was based on a study that showed 115mg of intravenous Emend for injection was biologically equivalent to 125mg of oral Emend.
Emend for injection (115mg) provides a new option for patients receiving an antiemetic on day one of their chemotherapy. Emend for injection (115mg) may be substituted for the 125mg oral capsule of Emend on day one and is administered 30 minutes prior to the initiation of chemotherapy over a 15-minute period.